Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,919 total articles
Microsoft is trading near pre-COVID valuation multiples (P/E ~22) despite accelerating cloud and AI revenue and $77.4B in free cash flow. The stock looks technically oversold (RSI ~24.7) after a sector-wide derating. This trade targets a mean-reversion to a more constructive mid-cycle multiple: entry $363.50, stop $345.00, target $420.00 over a mid…
Ciena sits at the physical layer that hyperscalers and cloud providers must buy to feed AI models. Strong order backlog, double-digit revenue tailwinds and healthy free cash flow argue for a buy-on-pullback approach. This trade plan targets a measured rebound while acknowledging valuation and execution risks.
Symbotic (SYM) is a leading warehouse automation specialist with a $22B+ backlog, improving margins, and substantial free cash flow. The stock has pulled back into the high-$40s after a post-earnings wobble. I view the current price as a tactical buying opportunity for a mid-term swing trade, sized for disciplined risk management.
ASE (ASX) looks like an actionable long: the stock is digesting a pullback near $20.88 while industry reports point to multi-year growth in high-end packaging and a capacity squeeze for premium solutions. We lay out a mid-term trade with precise entry, stop and target, plus the macro and company-specific catalysts that could re-rate ASE's multiple.
Hillman Solutions is a specialty distributor of fasteners, keys and merchandising solutions showing steady sales growth, free cash flow generation and a valuation that looks reasonable on an EV/EBITDA basis. This trade idea buys a clear recovery narrative — market-share gains in retail merchandising and pricing leverage — with a disciplined stop un…
General Dynamics (GD) just booked a $15.4 billion Navy award for Columbia-class submarines. The contract materially de-risks a large portion of near-term revenue for the Marine Systems business and reinforces free cash flow generation. We outline a tactical long with an entry at $341.00, a stop at $325.00 and a target of $370.00 over a 180 trading-…
Trilogy Metals (TMQ) is a $563M market-cap explorer/developer of the Ambler District in Alaska. The stock is a speculative proxy on executive and federal policy toward domestic critical minerals, plus progress on the company’s 2026 $35M program with South32. This trade idea outlines an entry at $3.25, a stop at $2.60 and a $6.50 target over a 180 t…
Dana Incorporated just lifted its quarterly dividend and doubled its buyback authorization timeline, signaling capital-return confidence while reporting margin improvement. With free cash flow of $298M, EV/EBITDA of 9.7 and room to re-rate toward its 52-week high, Dana looks like a pragmatic tactical long. We lay out an entry, stop and target for a…
State Street is trading at a modest multiple versus earnings and book value despite strong fee revenue trends and record assets under custody. With a current price of $123.44, a trailing EPS near $9.75 and an EV that belies its free cash flow generation, the stock offers a risk/reward profile attractive for a mid-term long. This trade idea lays out…
Willdan Group's combination of improving margins, recurring municipal/utility work and a much-lower valuation base after a 2025 reset creates a compelling mid-term trade. Enter near $76, stop $68, target $110 over a 45-trading-day horizon, with a favorable risk/reward if the company sustains cash flow and backlog conversion.
Cryoport is executing infrastructure and product rollouts that materially lower per-shipment costs and expand addressable capacity for cell and gene therapy logistics. With a market cap below $400M, improving margins, positive ROE/ROA, and a path to near-term breakeven, the stock offers a favorable risk-reward for a position trade. Entry at $7.90, …
Janus International (JBI) looks increasingly attractive at current levels. The stock trades near its 52-week low while the company generates strong free cash flow, carries meaningful cash on the balance sheet, and sits at valuation multiples that imply recovery potential. This trade idea outlines an actionable long with entry, stop, and target alon…
Shake Shack reported 22% revenue growth in Q4 and is guiding to meaningful unit expansion in 2026 while free cash flow is beginning to show positive momentum. At $83.62, the stock trades at an EV/sales of ~2.2 and a lofty P/E near 70 but with improving operating leverage and $1.47B of cash that supports share-price optionality. This trade idea lays…
Badger Meter has reset materially from 2025 highs and now offers a buyable mix of recurring software revenue growth, improving margins and a fortress balance sheet. Valuation has come in to a reasonable multiple for a mid-teens growth story; this note lays out an actionable long-term trade with entry, stop and target and the catalysts and risks tha…
Clorox (CLX) offers a sensible trading opportunity for income-oriented investors able to tolerate a medium level of company-specific risk. At roughly $102 per share, the stock yields near 4.8%, trades at a mid-teens P/E, and is sitting close to its 52-week low after a margin squeeze and a retailer inventory reset shaved expected sales and EPS. The …
Uber is getting dinged by headlines around autonomous partnerships and macro noise, but fundamentals - $9.09B free cash flow, a $143.9B market cap, and healthy margins - suggest the stock is mispriced for a 11-45 trading day rebound. This trade idea lays out an entry, stop, targets, catalysts and the specific risks that could derail the setup.
Corcept Therapeutics popped after the FDA approved Lifyorli for platinum-resistant ovarian, fallopian tube and primary peritoneal cancer. The regulatory green light materially reduces binary regulatory risk and creates a clear commercial catalyst. We upgrade to a buy and lay out an actionable trade: entry $38.12, stop $31.00, primary target $60.00 …
Castle Biosciences is set up for a meaningful re-rating as prospective validation of its DecisionDx-Melanoma i31-SLNB test reduces clinical uncertainty for sentinel lymph node management. With a $699.6M market cap, low leverage, positive free cash flow, and oversold technicals, we outline a mid-term trade to capture upside while keeping strict risk…
NetApp is trading at a mid-teens P/E with healthy free cash flow and a dividend, while industry tailwinds (hybrid cloud, AI workloads, SAN refresh cycles) support rising billings. Technicals show bullish momentum and short interest remains elevated, supplying squeeze potential. We recommend a mid-term swing buy with a clear entry, stop and target t…
Liberty Media's Formula One vehicle looks vulnerable to a near-term pullback despite durable long-term fundamentals. Short a tactical 10-trading-day trade around $76.94 with a tight stop, then consider accumulating for a 180-trading-day recovery if the market confirms lower levels.
SS Innovations (SSII) is a sub-$1B surgical robotics name showing clear commercial progress: Q2 2025 revenue doubled to $10.0M, system installations are increasing and the company is professionalizing its finance and operations team. That combination — real top-line growth, improving governance, and an AI-enabled platform — supports a long idea wit…
Indivior reported a FY25 beat and reiterated a clear playbook: grow SUBLOCADE penetration while reshaping the balance sheet. With guidance for 2026 calling for $1.125–$1.195B in revenue and management upsizing a $450M convertible issue to repay debt and buy back stock, the risk/reward favors a long over the next 180 trading days. Technicals show ne…
Marvell is showing clearer top-line momentum driven by AI and networking design wins. Management's guidance and recent quarter growth point to accelerating data-center revenue, while valuation and cash flow leave room for upside. This trade idea lays out an entry at the intraday level, a protective stop, and targets across a mid-to-long-term horizo…
CVR Energy (CVI) is a cash-flow leveraged refiner with a three-legged business - petroleum refining, renewables and nitrogen fertilizer - trading at a modest EV/EBITDA and offering a clear swing trade: enter near $35.00, stop $31.00, target $42.00 over a 45-trading-day horizon if macro spreads hold.
Meta is a high-quality franchise trading well below its highs after a volatile stretch for growth stocks. I want to be long, but only on a deeper pullback. Buying at $450 brings valuation to ~19x earnings and improves the risk-reward materially. This trade idea outlines the entry, stop, target, catalysts, and what would change my mind.
